• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Flunixin transdermal solution has an expanded indication

February 28, 2023

The pour-on NSAID for cattle is now FDA-approved for control of fever with mastitis

An expanded indication for flunixin transdermal solution (Banamine Transdermal; Merck Animal Health [MAH]) has been approved by the FDA. The new indication is for the control of fever with acute mastitis and a short milk withhold of 48 hours, according to MAH.

“This new indication means [flunixin transdermal solution] can be given with confidence to lactating cows,” said Scott Nordstrom, DVM, director of livestock innovation and discovery for MAH, in an organizational release. “With simple, pour-on administration along the animal’s back, [this product] saves time and labor costs while getting cows back into the milking string fast.”

In a multisite field study, 95% of dairy cows with acute mastitis had a reduction in fever of 2° F or more 6 hours after treatment with flunixin transdermal solution. That compared to 35% of untreated controls.

“Studies also show that a single dose of [flunixin transdermal solution] is absorbed into the bloodstream within minutes2 and has a long duration of activity at the site of inflammation3,” said Nordstrom. “This gives cattle the best opportunity to recover quickly and return to productivity.”

Advertisement

Introduced in 2018, flunixin transdermal solution is the only FDA-approved product for pain control in a food-producing animal, and the only nonsteroidal, anti-inflammatory (NSAID) cattle product available as a pour-on. It is a prescription product labeled for control of fever associated with bovine respiratory disease and acute mastitis, and for control of pain associated with foot rot.

“Caregivers can see visible results from relieving pain and fever symptoms in animals,” said Nordstrom.

According to MAH, flunixin transdermal solution is easy to administer, and it eliminates the treatment process associated with intravenous administration, which is the administration route of previous NSAIDs. Workers can easily administer the therapy without extensive training. The precalibrated packaging and red-colored solution help ensure the correct dose is given every time. The unique bottle design also makes it easy to apply topically on dry skin in a narrow strip down the animal’s midline from the withers to the tail head.

Reference

Merck Animal Health receives US FDA approval of expanded indication for Banamine Transdermal (flunixin transdermal solution). News release. Merck Animal Health. February 15, 2023. Accessed February 28, 2023. https://www.merck-animal-health-usa.com/newsroom/merck-animal-health-receives-u-s-fda-approval-of-expanded-indication-for-banamine-transdermal-flunixin-transdermal-solution

Related Content:

FDAPharmacy
What is GFI #256 and how does it impact my practice?
What is GFI #256 and how does it impact my practice?
Porcine parvovirus vaccine demonstrates promise in clinical study
Porcine parvovirus vaccine demonstrates promise in clinical study
FDA's Center for Veterinary Medicine names new director
FDA's Center for Veterinary Medicine names new director

Advertisement

Latest News

3 Must-reads from Fetch Charlotte 2023

A practical approach to a fever of unknown origin

Bridge Club aims to bring groomers and veterinarians together

ABVS approves full recognition for shelter medicine practice

View More Latest News
Advertisement